Welcome to our dedicated page for Pacific Biosc news (Ticker: PACB), a resource for investors and traders seeking the latest updates and insights on Pacific Biosc stock.
PacBio (Pacific Biosciences of California, Inc., NASDAQ: PACB) is a life science technology company focused on advanced genetic sequencing, and its news flow reflects developments across genomics research, collaborations, and financial performance. The company regularly issues press releases describing how its HiFi long-read sequencing platforms are being adopted in human health, rare disease research, and other genomics applications.
Recent PacBio news highlights planned collaborations with organizations such as the n-Lorem Foundation and EspeRare to apply long-read whole-genome sequencing in research on individualized antisense oligonucleotide therapies for ultra-rare and nano-rare genetic diseases. Other coverage includes projects where PacBio HiFi sequencing is used as a first-line whole-genome approach in studies of Sudden Unexplained Death in Childhood, and multi-center research through the HiFi Solves Consortium evaluating the clinical research utility of HiFi genomes in complex genomic regions.
Investors and researchers following PACB news will also find updates on technology advances, such as the community-developed CiFi long-read 3C method that integrates chromatin conformation capture with HiFi sequencing, and regulatory milestones achieved through partners like Berry Genomics in China with the Sequel II CNDx system. Financial news includes quarterly and preliminary annual revenue announcements, details on instrument and consumable performance, and commentary on new sequencing chemistries and assay portfolios.
This PACB news page on Stock Titan aggregates these types of announcements so readers can track PacBio’s research collaborations, technology developments, regional partnerships, and earnings-related updates in one place. Users interested in genomic sequencing, long-read technologies, and the business outlook for PacBio can review the latest press releases and historical news items to understand how the company’s platforms are being used and how management describes its progress.
PacBio (NASDAQ: PACB) reported preliminary unaudited revenue of $44.6M for Q4 2025 (+14% YoY) and $160.0M for full year 2025 (+4% YoY).
Q4 drivers included higher Revio and Vega shipments and a record $21.6M in consumables revenue. Instrument revenue declined to $17.3M in Q4 and $53.8M for 2025 versus prior-year instrument revenue of $65.8M. Service and other revenue rose to $5.7M in Q4 and $24.3M for 2025.
System placements: Revio 21 in Q4 (61 for 2025) and Vega 42 in Q4 (140 for 2025). Ending cash, cash equivalents, and investments were about $279.5M. Results are preliminary and expected to be finalized in the 2025 Form 10-K and a February earnings call.
PacBio (NASDAQ: PACB) and UC Davis researchers introduced CiFi, a community-developed method that combines multi-contact chromatin conformation capture (3C) with PacBio HiFi long-read sequencing to produce chromosome-scale, haplotype-resolved assemblies from a single Revio sequencing run.
CiFi generates long, concatemeric HiFi reads that capture multiple chromatin interactions per molecule, improving mapping in repetitive regions, enabling multi-contact resolution, and reducing input material, libraries, and sequencing runs. A Nature Communications publication and demonstration on prairie and meadow vole produced uncurated assemblies with scaffold N50 values exceeding 100 million base pairs and telomeric sequence at many scaffold ends.
PacBio (NASDAQ: PACB) announced management will present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026 at 10:30 AM PT (1:30 PM ET) in San Francisco.
A live webcast will be available on the company investor site and a replay will be posted for at least 30 days after the event.
PacBio (NASDAQ: PACB) said management will participate in a fireside chat at Piper Sandler’s 37th Annual Healthcare Conference on Wednesday, December 3, 2025 at 11:30 AM ET in New York.
A live webcast will be available on the company investor site at investor.pacificbiosciences.com, with a replay accessible for at least 30 days after the event.
PacBio (NASDAQ: PACB) announced management will participate in three investor conferences the week of November 18–19, 2025: Wolfe Research Healthcare Conference in New York, Jefferies Global Healthcare Conference in London, and Stephens Annual Investment Conference in Nashville.
Scheduled events include fireside chats on Nov 18 at 8:40 AM ET (Wolfe) and Nov 19 at 10:00 AM CT (Stephens); Jefferies meetings will be 1x1 sessions on Nov 19. Live webcasts of the fireside chats will be available at the company investor site, with replays available for at least 30 days.
PacBio (NASDAQ: PACB) reported Q3 2025 results for the quarter ended September 30, 2025. Revenue was $38.4M versus $40.0M a year ago; instrument revenue fell to $11.3M while consumables rose to $21.3M. GAAP gross profit was $15.9M and non-GAAP gross margin improved to 42% from 33% a year earlier. Non-GAAP operating expenses were $53.9M versus $62.4M in Q3 2024. Non-GAAP net loss narrowed to $36.8M (non-GAAP EPS $0.12). Cash and investments totaled $298.7M.
Product and program updates include the new SPRQ-Nx chemistry (targeting up to 40% sequencing cost reduction), Class III device registration in China for Sequel II CNDx, expanded PureTarget assays, and Revio selections for major genomics projects.
PacBio (NASDAQ: PACB) announced a multi-center preprint from the HiFi Solves EMEA Consortium showing that HiFi sequencing with Paraphase detected 100% of 125 known pathogenic variants in 86 individuals across 11 complex genomic regions.
The study used one SMRT Cell per sample with a median read length of 15.5 kb and mean per-base accuracy above 99.9%, demonstrating phasing, copy-number resolution, and detection of complex events (gene conversions) in paralogous regions previously inaccessible to short reads.
The consortium now spans 23 institutions in 16 countries, and authors say results support broader clinical adoption of high-accuracy long-read genomes for rare disease and diagnostic testing.
PacBio (NASDAQ: PACB) said the Sequel II CNDx system gained NMPA Class III medical device approval in China through its partner Berry Genomics on Nov 4, 2025.
This marks the first regulatory clearance of a clinical-grade long-read sequencer worldwide and enables Berry to offer an end-to-end long-read HiFi sequencing workflow in China, initially targeting thalassemia carrier, prenatal, newborn, and rare-disease testing. The system delivers long reads (≥20 kb) with high accuracy, detecting SNVs, indels, CNVs, SVs, repeat expansions and enabling phasing in a single run. PacBio and Berry plan to expand clinical assays and support deployment with AI analysis and local partnerships to reduce turnaround times and increase diagnostic yield.
PacBio (NASDAQ: PACB) will report third quarter 2025 financial results and host a conference call on Wednesday, November 5, 2025 at 4:30 PM ET (1:30 PM PT). The call will be webcast and available at https://investor.pacificbiosciences.com/.
Listen live via internet or by phone: toll-free 1-888-349-0136 or international 1-412-317-0459. Dial-in participants should join 10 minutes early and request to join the "PacBio Q3 Earnings Call".
PacBio (NASDAQ: PACB) announced SPRQ-Nx chemistry and consumables for Revio and Vega to reduce HiFi genome sequencing costs and add multiomic and regulated‑lab features. PacBio says customers at scale could see up to a 40% cost reduction, bringing per‑genome costs to under $300, with beta testing on Revio beginning November 2025 and commercial availability in 2026. Beta participants can purchase 384 genomes of reagents at about $250 per genome.
Other upgrades include 5hmC epigenetic detection, faster Vega runs (2–4 hours), 21 CFR Part 11 authentication and audit logging, and long‑term support for Revio and Vega through 2032.